Skip to main navigation Skip to search Skip to main content

Clinical course of COVID-19 among immunocompromised children: a clinical case series

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Infection with SARS-CoV-2 represents a great source of concern and a new threat for immunocompromised patients. Limited studies are available on COVID-19 in immunocompromised children. This case series aimed to evaluate the clinical and laboratory characteristics, management and outcomes of COVID-19 in five children immunocompromised due to different underlying conditions. All had mild symptoms or were asymptomatic at presentation. All had a benign course of illness. No changes or delays in their treatment regimens occurred, and none experienced a relapse of the original disease, developed severe COVID-19 or died. However, these cases showed a prolonged duration of virus shedding. This report suggests that immunocompromised paediatric patients may not be at a higher risk of developing severe COVID-19. However, further studies are required to elaborate on the pathogenesis of COVID-19 in this vulnerable group.

Original languageEnglish
Article numbere237804
JournalBMJ Case Reports
Volume13
Issue number10
DOIs
StatePublished - 31 Oct 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • immunology
  • infectious diseases
  • paediatrics

Fingerprint

Dive into the research topics of 'Clinical course of COVID-19 among immunocompromised children: a clinical case series'. Together they form a unique fingerprint.

Cite this